Thursday, April 25, 2024 4/25/2024

Pharmacologic modulation of innate immune dysfunction in heterotopic ossification

Award Number: R01AR073015
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT Heterotopic ossification is a rare but devastating condition of inappropriate bone formation. Although immune system activity is a critical contributor to heterotopic ossification, we lack a clear understanding of how the immune system drives bone formation. Fibrodysplasia ossificans progressiva (FOP) is a genetic disease of massive heterotopic ossification that is associated with inflammatory “flares” that can occur after injury. We recently found that sera from FOP patients have increased levels of pro-inflammatory cytokines at baseline. Furthermore, primary FOP monocytes showed increased responsiveness to LPS, a ligand that stimulates the TLR4 pathway, but not to other ligands that activate other TLR receptors. These preliminary results lead to our central hypothesis that FOP is an autoimmune disease caused by inappropriate activation of the innate immune system. Although there are currently no effective treatments for FOP, retinoic acid receptor-¿ (RAR-¿) agonists can inhibit heterotopic ossification in mouse models. UCSF is part of an ongoing multicenter Phase II/III program sponsored by Clementia Pharmaceuticals to study the efficacy of the RAR-¿ agonist palovarotene in blocking bone formation in FOP. Preliminary results from a completed randomized study (NCT02190747) and ongoing open label followup study (NCT02279095) indicate that palovarotene can decrease the amount of heterotopic bone formation in FOP subjects. The ongoing open label PVO-1A-202 (NCT02279095) and Phase III PVO-1A-301 (NCT03312634) interventional trials will be the parent studies for the proposed unique and time-sensitive opportunity to elucidate the immune mechanisms in FOP. In Aim 1, we will elucidate how FOP primary monocytes respond to endogenous TLR4 activation. We will assay FOP sera for known endogenous TLR4 activators that can be expressed after trauma, and test if FOP monocytes show increased responsiveness to the TLR4 activators such as HMGB1. In Aim 2, we will test if FOP primary monocytes sensitize endothelial cells to inflammation. We will use co-cultures to assay if FOP monocytes show increased chemotaxis towards FOP endothelial cells and if this is dampened by palovarotene. We will also test if FOP endothelial cells show enhanced pro-inflammatory cytokine expression in the presence of FOP monocytes. These assessments will also show if palovarotene affects immune cell function. In Aim 3, we will determine how ACVR1 and palovarotene change innate immune cell activation. We will use single cell RNAseq to elucidate how the ACVR1 R206H mutation changes the composition of peripheral immune cells, if palovarotene can normalize this profile, and if changes in cytokine production can be linked to inflammation and FOP clinical heterotopic bone formation. Our results will reveal critical inflammatory mechanisms that may provide the first mechanistic and diagnostic biomarkers for disease activity in FOP. The results may also improve our treatment strategies by identifying novel inflammatory targets that may be relevant to other conditions of heterotopic ossification.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$272 )
2024	2021	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	2/15/2024	NON-COMPETING CONTINUATION	-$272
														Subtotal = -$272

Issue Date FY: 2021 ( Subtotal = $344,641 )
2021	2021	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	6/16/2021	NON-COMPETING CONTINUATION	$344,641
														Subtotal = $344,641

Issue Date FY: 2020 ( Subtotal = $355,300 )
2020	2020	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	6/17/2020	NON-COMPETING CONTINUATION	$355,300
														Subtotal = $355,300

Issue Date FY: 2019 ( Subtotal = $347,776 )
2019	2019	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	7/1/2019	NON-COMPETING CONTINUATION	$347,776
														Subtotal = $347,776

Issue Date FY: 2018 ( Subtotal = $348,832 )
2018	2018	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	8/20/2018	NEW	$348,832
														Subtotal = $348,832

Grand Total All Awards = $1,396,277

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pharmacologic modulation of innate immune dysfunction in heterotopic ossification

Award Number: R01AR073015

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer